Amgen, Inc. (NASDAQ:AMGN) saw a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 10,361,375 shares, a growth of 20.2% from the February 15th total of 8,618,230 shares. Currently, 1.4% of the shares of the company are short sold. Based on an average trading volume of 4,385,991 shares, the days-to-cover ratio is currently 2.4 days.
In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the stock in a transaction that occurred on Wednesday, February 14th. The stock was sold at an average price of $174.18, for a total transaction of $265,624.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold a total of 4,575 shares of company stock valued at $838,064 over the last ninety days. 0.19% of the stock is owned by insiders.
A number of institutional investors have recently added to or reduced their stakes in the business. FMR LLC increased its position in Amgen by 4.8% during the second quarter. FMR LLC now owns 56,999,572 shares of the medical research company’s stock worth $9,817,037,000 after buying an additional 2,587,041 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Amgen by 0.9% in the second quarter. Vanguard Group Inc. now owns 52,146,935 shares of the medical research company’s stock valued at $8,981,266,000 after purchasing an additional 489,720 shares during the period. BlackRock Inc. grew its position in shares of Amgen by 1.9% in the second quarter. BlackRock Inc. now owns 49,451,203 shares of the medical research company’s stock valued at $8,516,980,000 after purchasing an additional 909,689 shares during the period. Bank of New York Mellon Corp grew its position in shares of Amgen by 1.7% in the third quarter. Bank of New York Mellon Corp now owns 8,166,002 shares of the medical research company’s stock valued at $1,522,551,000 after purchasing an additional 140,117 shares during the period. Finally, Geode Capital Management LLC grew its position in shares of Amgen by 2.5% in the fourth quarter. Geode Capital Management LLC now owns 8,110,133 shares of the medical research company’s stock valued at $1,407,552,000 after purchasing an additional 199,838 shares during the period. 79.53% of the stock is owned by institutional investors.
NASDAQ AMGN traded down $4.43 during mid-day trading on Monday, hitting $166.05. The stock had a trading volume of 4,756,745 shares, compared to its average volume of 5,220,746. Amgen has a 52-week low of $152.16 and a 52-week high of $201.23. The company has a market capitalization of $122,841.44, a P/E ratio of 13.20, a PEG ratio of 2.09 and a beta of 1.36. The company has a debt-to-equity ratio of 1.35, a current ratio of 5.49 and a quick ratio of 5.17.
Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Thursday, February 1st. The medical research company reported $2.89 earnings per share for the quarter, missing the consensus estimate of $3.03 by ($0.14). Amgen had a net margin of 8.66% and a return on equity of 30.87%. The firm had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.84 billion. During the same period in the previous year, the business earned $2.89 earnings per share. The business’s revenue for the quarter was down 2.7% on a year-over-year basis. research analysts expect that Amgen will post 13.25 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 8th. Investors of record on Thursday, May 17th will be paid a $1.32 dividend. This represents a $5.28 annualized dividend and a yield of 3.18%. The ex-dividend date is Wednesday, May 16th. Amgen’s payout ratio is currently 41.97%.
Amgen declared that its board has authorized a stock repurchase program on Thursday, February 1st that authorizes the company to buyback $10.00 billion in shares. This buyback authorization authorizes the medical research company to reacquire shares of its stock through open market purchases. Shares buyback programs are usually a sign that the company’s board believes its stock is undervalued.
A number of analysts have weighed in on AMGN shares. Oppenheimer reaffirmed a “buy” rating and set a $205.00 price objective on shares of Amgen in a research report on Tuesday, January 30th. Argus raised Amgen from a “hold” rating to a “buy” rating and increased their price objective for the stock from $192.33 to $220.00 in a research report on Tuesday, January 23rd. Piper Jaffray reaffirmed a “buy” rating on shares of Amgen in a research report on Tuesday, January 2nd. Mizuho set a $192.00 price target on Amgen and gave the company a “buy” rating in a report on Thursday, December 28th. Finally, Goldman Sachs cut Amgen from a “conviction-buy” rating to a “buy” rating in a report on Friday, December 15th. Two investment analysts have rated the stock with a sell rating, fourteen have given a hold rating and eleven have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $191.26.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.